MUSC Hollings Cancer Center - Report to the Community 2026 - Flipbook - Page 10
Cancer Discoveries
Experimental drug
shows promise
for some patients
with advanced
prostate cancer
A
multi-institution clinical trial led by researchers at
MUSC Hollings Cancer Center has identi昀椀ed a
potential new treatment strategy for patients with
advanced prostate cancer whose disease has stopped
responding to standard hormone therapies.
The Phase II trial tested opaganib, an experimental oral
drug with roots in discoveries made at MUSC. Unlike
standard prostate cancer therapies that target hormones,
opaganib blocks a pathway involved in sphingolipid
metabolism – the way cells manage fats that in昀氀uence
survival and may contribute to cancer growth and
treatment resistance.
Researchers added opaganib to existing treatment in
66 men with metastatic prostate cancer whose
disease had already progressed, testing whether
the drug could overcome resistance and extend the
effectiveness of commonly used therapies. Although the
trial did not meet its primary goal, a subset of patients
showed meaningful signs of bene昀椀t, including declines in
prostate-speci昀椀c antigen levels and periods of
disease stabilization.
For Besim Ogretmen, Ph.D., whose research helped
lay the groundwork for opaganib, those responses
are important in patients with few remaining
treatment options.
“Even though it’s a small percentage, those are
real patients. We’re talking about people who
are bene昀椀ting from this treatment when others
have not worked.”
The researchers are now analyzing blood samples to
identify biomarkers that could reveal which patients are
most likely to respond to the drug, potentially paving the
way for a more precise treatment approach.
SELECT HIGH-IMPACT PUBLICATIONS
Cancer Research
Nature Communications
Alzheimer’s disease-associated amyloid beta precursor protein prevents aging
stress-induced mitophagy and fumarate depletion to improve anti-tumor immunity
Sphingosine kinase-2 inhibition promotes immunogenic differentiation of myeloidderived suppressor cells through an Acetyl-CoA carboxylase-phosphatidylcholine axis
Deshmukh A, Mehrotra S, Ogretmen B, Sahin O, Sonawane K
Gangaraju VK, Gangaraju V, Hill EG, Hill E, Mehrotra S, Ogretmen B, Peterson YK,
Peterson Y, Sahin O, Seal S
8 | MUSC Hollings Cancer Center